MINDACT trial data reveal certain women with luminal breast cancer may be undertreated with tamoxifen alone
Among women with hormone receptor (HR)-positive, HER2-negative breast cancer with a high clinical risk (determined…
Browsing: tamoxifen
Drug-light combo could offer control over CAR T-cell therapy
Bioengineers at the University of California San Diego are a step closer to making CAR…
AI reveals new breast cancer types that respond differently to treatment
Scientists have used artificial intelligence to recognise patterns in breast cancer and uncovered five new…
Diet high in leucine may fuel breast cancer’s drug resistance
About one in eight women in the United States will develop breast cancer in her…
Partner status influences sexual problems and self-efficacy in survivors of breast cancer
Vaginal dryness and painful intercourse are some of the more common adverse events of post-breast…
How a new breast cancer biomarker could help patients identify best treatment options
Dong-Xu Liu, Auckland University of Technology According to the latest GLOBOCAN cancer database, New Zealand’s…
SABCS 2018: Low-dose tamoxifen was safe and effective at reducing recurrence and new breast disease for patients with DCIS, LCIS, and ADH
Treatment with a low dose of tamoxifen (5 mg per day) halved the risk of…
Why women reject breast cancer preventing drug – new study
Rachael Thorneloe, University of Leeds and Samuel Smith, University of Leeds Women who have a…
ESMO 2018: One in six premenopausal early breast cancer patients do not adhere to hormonal therapy
Nearly one in six premenopausal women being treated for early stage breast cancer do not…
‘Evil’ proteins a force for good in estrogen receptor-positive breast cancer
Breast cancer is one of the most common cancers, striking 1 out of 8 women.…